Table 1.

First-line salvage therapy after ibrutinib progression/relapse

	N = 25 (%)∗	CR	PR	SD	PD
BR and BO	6 (24)	4	0	0	2
R2	4 (16)	1	3	0	0
Phosphatidylinositol-3-kinase inhibitor	3 (12)	0	1	2	0
IR or IO	3 (12)	0	1	1	1
Others†	9 (36)	1	2	4	2

BO, bendamustine and obinutuzumab; BR, bendamustine and rituximab; IO, ibrutinib and obinutuzumab; IR, ibrutinib and rituximab; R2, rituximab and lenalidomide (revlimid).

^∗Among the 43 patients who progressed/relapsed after ibrutinib, only 25 received subsequent therapy.

^†Others: 5 included alkylator-based (nonbendamustine) therapies, 1 platinum-based, 2 anti-CD20 monoclonal antibodies, and 1 BCL-2 inhibitor.